A Phase Ii Study Of Atezolizumab And Cobimetinib In Pd-1/Pd-L1 Inhibitor Resistant Or Refractory Non-Small Cell Lung Cancer: Etctn #10166.

Stephen V. Liu,Richard Delmar Hall,Andreas Nicholas Saltos,Gregory Alan Otterson,Ming Tony Tan,Sacha Gnjatic,Ryan D. Gentzler,Tawee Tanvetyanon,Helen X. Chen,Elad Sharon

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 1|浏览24

暂无评分

摘要

TPS9638Background: Use of checkpoint inhibitors, alone or with chemotherapy, has emerged as the preferred standard treatment for patients with advanced, driver-negative non-small cell lung cancer (...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要